HONG KONG, March 5, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world's first PD-1/CTLA-4 bispecific...
Hence then, the article about akeso announces completion of patient enrollment in the phase iii clinical trial of cadonilimab for adjuvant treatment of high risk recurrent hepatocellular carcinoma was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma )
Also on site :
- My Wife Doesn’t Know I Watched Her Cheat On Me. My Reaction Might Shock Us Both.
- The Good Ship Murder Christmas special cast: Meet the characters
- Eight fire crews tackling blaze at West Midlands Wetherspoon pub